For the treatment of adult patients with the following criteria:
- clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early symptomatic AD),
- heterozygous apolipoprotein-in E-ε4 (ApoE-ε4) carriers or
- ApoE-ε4 non-carriers
- confirmed amyloid pathology (amyloid PET, cerebrospinal fluid examination).
Before starting treatment, the benefits and the potential risk of serious side effects associated with ARIA must be weighed up (including pre-existing risk factors!).
Treatment only by a specialized physician qualified in the field with clinical experience in AD and prompt access to MRI examination (monitoring of undesirable side effects immediately and outside the intended examination protocol if necessary!)
MRI findings only by a specialist trained and experienced in cMRI and the specific changes!
ApoE-ε4 genotyping by a CE-marked in-vitro diagnostic device (IVD), stating the corresponding intended use! (If a CE-marked IVD is not available, an alternative, validated test procedure must be used)
For further information see technical information!